KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma.

Sumanta K Pal, Thomas Powles, Ravindran Kanesvaran, Javier Molina-Cerrillo, Darren R Feldman, Pedro Barata, Mohan Liu, Aarohi Bhatt, Zhong Wang, Prachi Nandoskar, Cristina Suarez

Future Oncol 21(7) 787-794

PMID40008409
PMCIDPMC11916370
DOI10.1080/14796694.2025.2458395
发表日期2025-02-26
摘要

摘要

Management of advanced non-clear cell renal cell carcinoma (nccRCC) is challenging due to disease rarity and heterogeneity. The combination of multi-targeted tyrosine kinase inhibitor (TKI) with immune checkpoint inhibitor (ICI) has emerged as an effective treatment strategy, but well-designed, phase III randomized clinical trials are needed to demonstrate superiority over current treatment options. Zanzalintinib is a novel, multi-targeted TKI that has demonstrated promising preclinical anti-tumor activity in combination with ICIs. STELLAR-304 is a phase III trial evaluating first-line zanzalintinib plus nivolumab versus sunitinib in advanced nccRCC. Primary endpoints are progression-free survival and objective response rate. Secondary endpoint is overall survival. To our knowledge, STELLAR-304 is the first phase III study assessing a TKI-ICI combination in nccRCC patients across multiple subtypes.Clinical Trial Registration: This trial is registered at ClinicalTrials.gov (identifier: NCT05678673).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。